Antagonizing the parathyroid calcium receptor stimulates parathyroid hormone secretion and bone formation in osteopenic rats

Maxine Gowen, … , Edward F. Nemeth, John Fox

*J Clin Invest.* 2000;105(11):1595-1604. [https://doi.org/10.1172/JCI9038](https://doi.org/10.1172/JCI9038).

Parathyroid hormone (PTH) is an effective bone anabolic agent, but it must be administered parenterally. An orally active anabolic agent would provide a valuable alternative for treating osteoporosis. NPS 2143 is a novel, selective antagonist (a “calcilytic”) of the parathyroid cell Ca\(^{2+}\) receptor. Daily oral administration of NPS 2143 to osteopenic ovariectomized (OVX) rats caused a sustained increase in plasma PTH levels, provoking a dramatic increase in bone turnover but no net change in bone mineral density. Concurrent oral administration of NPS 2143 and subcutaneous infusion of 17\(\beta\)-estradiol also resulted in increased bone turnover. However, the antiresorptive action of estrogen decreased the extent of bone resorption stimulated by the elevated PTH levels, leading to an increase in bone mass compared with OVX controls or to either treatment alone. Despite the sustained stimulation to the parathyroid gland, parathyroid cells did not undergo hyperplasia. These data demonstrate that an increase in endogenous PTH secretion, induced by antagonism of the parathyroid cell Ca\(^{2+}\) receptor with a small molecule, leads to a dramatic increase in bone turnover, and they suggest a novel approach to the treatment of osteoporosis.

Find the latest version:

[http://jci.me/9038-pdf](http://jci.me/9038-pdf)
Antagonizing the parathyroid calcium receptor stimulates parathyroid hormone secretion and bone formation in osteopenic rats

Maxine Gowen,1 George B. Stroup,1 Robert A. Dodds,1 Ian E. James,1 Bart J. Votta,1 Brian R. Smith,2 Pradip K. Bhatnagar,3 Amparo M. Lago,3 James F. Callahan,3 Eric G. DelMar,4 Michael A. Miller,4 Edward F. Nemeth,4 and John Fox4

1Department of Bone and Cartilage Biology, 2Department of Drug Metabolism, and
3Department of Medicinal Chemistry, SmithKline Beecham Pharmaceuticals Inc., King of Prussia, Pennsylvania, USA
4NPS Pharmaceuticals Inc., Salt Lake City, Utah, USA

Address correspondence to: John Fox, NPS Pharmaceuticals Inc., 420 Chipeta Way, Salt Lake City, Utah 84108, USA.
Phone: (801) 583-4939; Fax: (801) 583-4961; E-mail: jfox@npsp.com.

Parts of this work were presented at the Second Joint Meeting of the American Society for Bone and Mineral Research and the International Bone and Mineral Society, San Francisco, California, USA, December 1–6, 1998, and have appeared in abstract form (1998. Bone. 23[Suppl.]:S163).

Received for publication December 2, 1999, and accepted in revised form April 19, 2000.

Parathyroid hormone (PTH) is an effective bone anabolic agent, but it must be administered parenterally. An orally active anabolic agent would provide a valuable alternative for treating osteoporosis. NPS 2143 is a novel, selective antagonist (a “calcilytic”) of the parathyroid cell Ca2+ receptor. Daily oral administration of NPS 2143 to osteopenic ovariectomized (OVX) rats caused a sustained increase in plasma PTH levels, provoking a dramatic increase in bone turnover but no net change in bone mineral density. Concurrent oral administration of NPS 2143 and subcutaneous infusion of 17β-estradiol also resulted in increased bone turnover. However, the antiresorptive action of estrogen decreased the extent of bone resorption stimulated by the elevated PTH levels, leading to an increase in bone mass compared with OVX controls or to either treatment alone. Despite the sustained stimulation to the parathyroid gland, parathyroid cells did not undergo hyperplasia. These data demonstrate that an increase in endogenous PTH secretion, induced by antagonism of the parathyroid cell Ca2+ receptor with a small molecule, leads to a dramatic increase in bone turnover, and they suggest a novel approach to the treatment of osteoporosis.

sient increases in circulating PTH levels, if repeated on a daily basis, might produce an anabolic effect in bone (14). We showed previously that the induction of hypocalcemia by infusion of the calcium chelator EGTA raised circulating PTH to levels that were sufficient to stimulate bone formation in osteopenic rats (22). If this could be achieved with an orally active small molecule antagonist of the Ca\(^{2+}\) receptor, it might represent a novel anabolic therapy for osteoporosis. The identification and pharmacological characterization of such a molecule, NPS 2143, has recently been described (23). Briefly, screening of compound libraries in human embryonic kidney (HEK 293) cells that stably express the human parathyroid Ca\(^{2+}\) receptor identified a compound that was a weak (IC\(_{50}\) = 11 \(\mu\)M) inhibitor of increases in cytoplasmic Ca\(^{2+}\) levels induced by extracellular Ca\(^{2+}\). Structural modification of this compound yielded NPS 2143, a more potent (IC\(_{50}\) = 43 nM) and selective compound (Figure 1). In particular, NPS 2143 did not inhibit cytoplasmic Ca\(^{2+}\) responses to glutamate in HEK 293 cells engineered to express the structurally related metabotropic glutamate receptors, or to \(\gamma\)-amino butyric acid (GABA) in similar cells expressing similarly related GABA\(_{\text{A}}\) receptors (24). Moreover, NPS 2143 stimulated PTH secretion from bovine parathyroid cells in vitro (EC\(_{50}\) = 39 nM) and increased plasma PTH levels when administered to normal rats by intravenous infusion. Here we describe the effect of daily oral administration of NPS 2143 on bone in aged ovariectomized (OVX) rats with established osteopenia, and demonstrate for the first time that antagonism of the parathyroid cell Ca\(^{2+}\) receptor in vivo by an orally active small molecule leads to an increase in bone turnover.

Methods

OVX rat studies

Animals, diets, and surgery. Animal protocols were approved by the Animal Care and Use Committee at SmithKline Beecham Pharmaceuticals Inc. Six-month-old virgin Sprague-Dawley rats were purchased from Charles River Laboratories Inc. (Wilmington, Massachusetts, USA). They were provided with unrestricted access to tap water and commercial rodent chow (Diet 5001; PMI Nutrition International, Brentwood, Missouri, USA) throughout the study. When the rats were 7 months old, they were subjected either to a bilateral ovariectomy or to sham surgery, and then held for a further 3 months to allow the development of osteopenia. At that time, each rat was anesthetized with isoflurane, and bone mineral density (BMD) was quantified in the lumbar spine, distal femur, and proximal tibia by dual-energy x-ray absorptiometry (QDR-4500A; Hologic Inc., Waltham, Massachusetts, USA).

Study 1. The OVX rats were divided into 3 groups (\(n = 10\)–14 per group) that were matched by lumbar BMD. One group of sham-operated rats (\(n = 10\)) and one group of OVX rats received a daily oral dose by gavage of the same vehicle (5 mL/kg) used to formulate NPS 2143, a 20% aqueous solution of 2-hydroxypropyl-\(\beta\)-cyclodextrin (Cerestar, Hammond, Indiana, USA). The second OVX group received NPS 2143 (100 \(\mu\)mol/kg, per os), and the third OVX group received subcutaneous injection (5 \(\mu\)g/kg) of synthetic rat PTH(1-34) (Bachem California, Torrance, California, USA), dissolved in 2% cysteine-HCl, pH 4.5, containing 0.1% BSA. The dose of NPS 2143 was chosen because preliminary studies in normal rats showed that it induced a consistent and maximal increase in plasma PTH levels. The 5 \(\mu\)g/kg dose of PTH was shown previously to be an effective anabolic dose in OVX rats, and to increase plasma PTH levels by an amount similar to that achievable by acute stimulation of PTH secretion (22).

Treatment continued daily for 8 weeks. BMD was again determined in vivo at treatment weeks 4 and 8. All animals received calcine (10 mg/kg, subcutaneously) 10 days and 3 days before sacrifice. At the end of the study, animals (3–4 at each time point) were sacrificed at varying times after the final dose, and blood was collected for PTH analysis. The tibiae were removed for histomorphometric analysis.

Study 2. Animals were prepared as described in Study 1. Groups consisted of sham-operated and OVX controls that received vehicle (20% 2-hydroxypropyl-\(\beta\)-cyclodextrin, per os), and three additional OVX groups that received either NPS 2143 (100 \(\mu\)mol/kg, per os); 17\(\beta\)-estradiol, administered as a continuous infusion using a subcutaneously implanted pellet (0.01 mg per 90 days; Innovative Research of America, Sarasota, Florida, USA); or NPS 2143 together with 17\(\beta\)-estradiol. Dosing continued daily for 5 weeks. BMD was determined in vivo at baseline and at the end of the study. All rats received calcine (10 mg/kg, subcutaneously) at 10 days and 3 days before sacrifice, at which point the tibiae were collected for histomorphometric analysis. To evaluate the effects of treatment on parathyroid cell proliferation, five animals in each treatment group were infused with 5-bromo-2-deoxyuridine (BrdU), a thymidine analogue. Model 2001 Alzet osmotic minipumps (ALZA Corp., Palo Alto, California, USA) were filled with BrdU (250 mg/mL) dissolved in dimethyl sulfoxide and propylene glycol (1:1 vol/vol), and implanted subcutaneously 4 days before necropsy.

Bone histomorphometry. Bone samples from both studies were dehydrated with increasing concentrations of ethanol, defatted in acetone, and embedded in methyl methacrylate (Polysciences Inc., Warrington, Pennsylvania, USA). Longitudinal undecalcified sections (5 \(\mu\)m) of the proximal tibia were cut on a Leica microtome (SM2500S; Leica Microsystems Inc., Deerfield, Illinois, USA). In Study 1, sections were stained with von Kossa stain; in Study 2 the tissue blocks were prestained with Villanueva stain (25). Histomorphometric analysis was carried out in a blinded fashion, using the Optimus system (Optimus Corp., Seattle, Washington, USA) in Study 1 and the Osteomeasure system (Osteometrics...
Inc., Decatur, Georgia, USA) in Study 2. Measurements within the tibial metaphysis were restricted to a mean tissue area of approximately 8 mm², beginning 1 mm below the growth plate. Primary measurements included total bone and marrow area (B.Ar, mm²), trabecular bone area (Tb.Ar, mm²), bone perimeter (mm), single- and double-labeled perimeter (sL.Pm, dL.Pm; mm), osteoid perimeter (O.Pm, mm), and eroded perimeter (E.Pm, mm). Derived indices included Tb.Ar (%), trabecular number (Tb.N, mm⁻¹), trabecular thickness (Tb.Th, μm), trabecular separation (Tb.Sp, μm), mineral appositional rate (MAR, μm/day), and labeled perimeter (L.Pm, %). Also included were bone formation rate (BFR) indices designated surface-referent (BFR/Tb.Pm, μm³/m²/year), area-referent (BFR/Tb.Ar, % per year), and tissue-referent (BFR/B.Ar, % per year).

All nomenclature and abbreviations are consistent with those recommended by the American Society for Bone and Mineral Research (26).

Parathyroid cell proliferation

Tissue processing. The thyroid/parathyroid complex and ileum were collected at necropsy and fixed for 24 hours at 4°C with 10% phosphate-buffered formalin. After sequential dehydration with ethanol and xylene, the tissues were embedded in Surgipath EM-400 (Surgipath Medical Industries Inc., Richmond, Illinois, USA). The thyroid/parathyroid complex with a portion of the adjoining trachea was cut into 3-μm-thick sections in the sagittal plane. The sections quantified were taken from the most central areas of the parathyroid gland. The ileum was cut into 3-μm-thick cross-sections.

Immunohistochemistry. To identify proliferating cells, BrdU-incorporated cells were detected using a BrdU immunostaining kit (Zymed Laboratories Inc., San Francisco, California, USA). After the slides were dewaxed and rehydrated, slides were incubated for 10 minutes with 3% hydrogen peroxide and methanol to block endogenous peroxidase. Slides were digested with 0.1% trypsin for 15 minutes at 37°C, rinsed with distilled water, and incubated with denaturing solution for 30 minutes at room temperature to denature DNA. Slides were then reacted with anti-BrdU monoclonal antibody at room temperature for 1 hour. The bound primary antibody was detected by the streptavidin-biotin immunoperoxidase method. Slides were developed with 3,3’-diaminobenzidine and counterstained with hematoxylin. BrdU was identified as dark brown staining in the nucleus. A Zymed BrdU-positive mouse intestine slide was used as a negative control by replacing the anti-BrdU monoclonal antibody with distilled water for detection of nonspecific binding.

Cell counting. Positive BrdU incorporation for each animal was confirmed in the epithelial cells of the ileum. For each animal, three separate slides of the parathyroid gland were quantified, and the total number of positive- and negative-staining nuclei were determined. The number of BrdU-positive and BrdU-negative cells were quantified at x200, and were expressed as a percentage of total cell number.

In vitro assays of osteoblast and osteoclast activity

The TF274 cell line, derived from immortalized human bone marrow stromal cells (27) and primary cultures of osteoblasts derived from explants of human trabecular bone (28), were used to assess some functional responses of osteoblasts. First, the effect of NPS 2143 on PTH receptor-mediated increases in cyclic AMP formation was quantified. Both cell types were incubated in quadruplicate with human PTH(1-34) (40 ng/200 μL) for 30 minutes at room temperature in the absence or presence of 0.1, 1.0, or 10.0 μmol/L NPS 2143. Reactions were terminated by acidifying the medium, and cellular lysis was facilitated by freezing. After thawing and centrifugation, cyclic AMP levels were determined in neutralized supernatants using a nonradioactive assay kit (Amersham Life Sciences Inc., Arlington Heights, Illinois, USA). TF274 cells were also used to assess the effects of NPS 2143 on alkaline phosphatase activity. Cells grown to confluence in Ham’s F-12 medium containing 1% FCS were incubated at 37°C for 48 hours in the absence or presence of PTH (20 ng/0.5 mL), and...
with or without 0.01, 0.1, or 1.0 μmol/L NPS 2143. Alkaline phosphatase activity appearing in the medium was measured colorimetrically (29).

Human osteoclasts were obtained by disaggregating fresh osteoclastoma tissue (27), and these isolated cells were then mixed with particles of bovine cortical bone as described recently (30). The mixture of cells and bone particles was incubated for 24 hours at 37°C in the absence or presence of various concentrations of NPS 2143. After incubation, the levels of the carboxy-terminal peptide of the \( \alpha \)1 chain of type I collagen in the medium were quantified using a competitive binding enzyme-linked immunoadsorbant assay kit (ref. 31; Osteometer MediTech Inc., Rodovre, Denmark). The results are expressed as percent inhibition of carboxy-terminal peptide levels in media derived from osteoclast/bone particle mixtures cultured in the absence of NPS 2143. IC\(_{50}\) was determined by manual extrapolation of concentration-response curves.

Fetal rat long bones were used to assess effects of NPS 2143 on bone resorption in a system containing a number of relevant cell types in a more physiological environment (32). Timed-pregnant Sprague-Dawley rats were injected subcutaneously with 200 μCi of \( ^{45}\)CaCl\(_2\) on day 18 of gestation, and were housed overnight before they were anesthetized with Innovar-Vet (Pittman-Moore, Mundelein, Illinois, USA) before sacrifice by cervical dislocation. The fetuses were removed aseptically, and the radii and ulnae were dissected free of surrounding soft tissue and cartilaginous ends. The bone rudiments were randomly sorted so that four rudiments were used at each concentration of NPS 2143 or vehicle (DMSO) control. The bone rudiments were cultured for 18–24 hours in BGJ\(_b\) medium (Sigma Chemical Co., St. Louis, Missouri, USA) containing 0.1% BSA. Then they were transferred to fresh medium and cultured for an additional 48 hours in the absence or presence of human PTH(1-34) (50 ng/mL) with or without various concentrations of NPS 2143. The \( ^{45}\)Ca released into the medium and retained in the bone rudiments (after solubilization in 5% trichloroacetic acid) was quantified by liquid scintillation spectrometry. The results are expressed as percent \( ^{45}\)Ca released from bone rudiments.

Biochemical assays. The concentrations of NPS 2143 in plasma were quantified by liquid chromatography/mass spectrometry (limit of detection, 10 ng/mL). Plasma PTH levels were measured using an N-terminal rat PTH immunoradiometric assay kit that exhibits 100% cross-reactivity between PTH(1-34) and PTH(1-84) (Immutopics International LLC, San Clemente, California, USA).

Statistical analyses. All results are shown as mean ± SE. The data were subjected to ANOVA and Fisher’s protected least significant difference test to determine the significance of differences between groups. \( P < 0.05 \) was used to signify a significant difference.

Results

Study 1: Small but sustained elevation of PTH levels increases bone turnover with no net gain or loss of bone

Animals that had undergone ovariectomy 3 months previously had significantly lower BMD at all three skeletal sites measured. The reductions were 15% at the lumbar spine and proximal tibia, and 24% at the distal femur. BMD in the proximal tibia was unaffected by daily treatment with NPS 2143, but was returned to pre-ovariectomy levels after 8 weeks of treatment with PTH (Figure 2). Similar changes were seen in the distal femur and lumbar vertebrae (not shown). Plasma PTH levels...
were measured after dosing in the last week of the experiment. PTH levels were elevated (> 100 pg/mL) within 30 minutes after dosing with NPS 2143; levels remained high for at least 4 hours (Figure 3). PTH levels in animals given the 5 μg/kg subcutaneous dose of PTH were similar to those dosed with NPS 2143, but had returned to baseline by 2 hours after the injection (Figure 3). The differences in the duration of the PTH response can be explained by sustained systemic exposure to NPS 2143. NPS 2143 levels were undetectable (< 10 ng/mL) at 24 hours.

The different plasma PTH profiles obtained under these two dosing conditions induced markedly different effects on bone turnover. Dynamic histomorphometric analysis of cancellous bone in the proximal tibial metaphysis showed that bone formation (% O.Pm and % L.Pm) was further elevated above the OVX control level by both PTH and NPS 2143 (Figure 5). MAR was unaffected by any treatment (data not shown). However, bone resorption, as measured by percent E.Pm, was significantly higher in the NPS 2143 group than in the PTH or OVX control groups. This is exemplified further by the dramatic increase in bone turnover (BFR/B.Ar) in rats treated with NPS 2143 compared with the other two groups (Figure 5). Thus, the modest but protracted elevation of PTH achieved by administration of NPS 2143 resulted in a dramatic increase in both bone formation and resorption, with no net bone gain or loss. PTH injections also increased both resorption and formation, but formation exceeded resorption, resulting in increased bone mass (Figure 2).

Study 2: Small but sustained elevation of PTH levels in the presence of an antiresorptive agent increases bone turnover with net bone gain

A second study was performed in animals in which NPS 2143 was administered daily for 5 weeks in the presence of estrogen. Figure 6 shows representative sections of proximal tibiae from sham-operated and OVX controls treated with vehicle, an OVX rat treated with 17β-estradiol alone, and an OVX rat treated with 17β-estradiol plus NPS 2143. It is obvious visually that coadministration of NPS 2143 and 17β-estradiol increased cancellous bone area over and above that achieved with 17β-estradiol alone. These changes were quantitated histomorphometrically; the results are shown in Table 1. Tb.Ar was 72% lower in OVX animals than in sham-operated animals, a loss that was not significantly restored by treatment with 17β-estradiol. Treatment with NPS 2143 alone also had no effect on OVX-induced osteopenia. However, NPS 2143 given in combination with 17β-estradiol resulted in a significant, twofold increase in percent Tb.Ar over the OVX group, an increase that was due primarily to an increase in Tb.Th (Table 1). The apparent small increase in Tb.N in rats given 17β-estradiol probably resulted from prevention of further cancellous bone loss during the treatment period. Treatment with 17β-estradiol alone completely reversed the OVX-induced increases in indices of bone formation and resorption (Figure 7). As was observed in Study 1, treatment with NPS 2143 alone also increased most of these indices above levels in OVX controls. However, in rats treated with NPS 2143 plus 17β-estradiol, tissue-referent BFR was significantly elevated compared with all other groups (Figure 7). Elevation of bone formation rate/tissue area shows that bone mass was increased in the area measured, reflecting new bone formation on bone surfaces that were not being remodeled, a classic feature of PTH action. This appears to be a result of a decrease in resorption (presumably due to concurrent estrogen treatment) relative to the NPS 2143–treated animals in the face of maintained elevation of bone formation (Figure 7).

These changes in histomorphometric indices of bone formation and resorption and in cancellous bone content were reflected by changes in BMD in the distal femur. BMD was 0.3725 ± 0.0095 g/cm² in the sham-operated rats at baseline, and changed little (final value 0.3744 ± 0.0068 g/cm²) during the 5-week treatment.
On average, only about 30 of the 6,000 cells (0.5%) had divided during the last 4 days of the study (Figure 9). In contrast, in the ileum, almost 100% of surface epithelial cells and about 30% of cells within the central compartment of the villus had taken up BrdU (not shown). The rate of cell division was not significantly affected by ovariectomy or by treatment with 17β-estradiol, NPS 2143, or both.

NPS 2143 has no direct effects on osteoblasts and osteoclasts in vitro

**Osteoblast activity.** Whereas PTH caused a 2.6-fold increase in cyclic AMP levels in TF274 osteoblastic cells, NPS 2143 (0.1–10.0 μmol/L) had no effect on either basal or PTH-induced cyclic AMP levels (Figure 10a). Essentially identical results were seen in primary human osteoblasts (not shown). PTH treatment of TF274 cells increased alkaline phosphatase activity 7.6-fold; the addition of NPS 2143 (0.01–1.0 μmol/L) did not affect either basal or PTH-stimulated activity (Figure 10b). NPS 2143 (10 μmol/L) tended to reduce the alkaline phosphatase response to PTH in TF274 cells, although this is more likely to be a result of cellular toxicity at this very high concentration.

**Osteoclast activity.** NPS 2143 had no effect on bone resorption by isolated human osteoclasts plated on bovine cortical bone particles at concentrations up to 3 μmol/L. In contrast, an inhibitor of cathepsin K, SB-240314 (28), inhibited this production with an IC₅₀ of 0.9 μmol/L. This assay is limited by its sensitivity to DMSO, so concentrations of NPS 2143 above 3 μmol/L could not be tested. In the fetal rat long bone assay, NPS 2143 inhibited resorption significantly, with an IC₅₀ of 11.3 ± 3.0 μmol/L.

**Discussion**

We have demonstrated that an orally active calcilytic compound can be designed that blocks the parathyroid Ca²⁺ receptor and thereby raises plasma PTH to levels that are sufficient to stimulate bone turnover. The pharmacokinetic characteristics of this molecule are such that, after oral administration, a prolonged elevation of PTH (> 4 hours) is obtained. In contrast, when PTH was elevated for up to 2 hours after PTH injection, bone

### Table 1

<table>
<thead>
<tr>
<th>Surgery</th>
<th>Treatment</th>
<th>Tb.Ar (%)</th>
<th>Tb.Th (μm)</th>
<th>Tb.N (mm⁻¹)</th>
<th>Tb.Sp (μm)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sham</td>
<td>Vehicle</td>
<td>35.9 ± 1.7</td>
<td>67.2 ± 2.3</td>
<td>5.33 ± 0.13</td>
<td>175 ± 8</td>
</tr>
<tr>
<td>OVX</td>
<td>Vehicle</td>
<td>9.9 ± 1.7A</td>
<td>60.9 ± 3.2</td>
<td>1.57 ± 0.23A</td>
<td>1193 ± 331A</td>
</tr>
<tr>
<td>OVX</td>
<td>Estradiol</td>
<td>14.8 ± 1.9A</td>
<td>58.3 ± 1.7</td>
<td>2.50 ± 0.30AB</td>
<td>716 ± 250</td>
</tr>
<tr>
<td>OVX</td>
<td>NPS 2143</td>
<td>8.6 ± 0.9A</td>
<td>56.6 ± 2.5A</td>
<td>1.50 ± 0.15AC</td>
<td>951 ± 100A</td>
</tr>
<tr>
<td>OVX</td>
<td>Estradiol + NPS 2143</td>
<td>20.7 ± 4.3AB,CD</td>
<td>73.0 ± 5.7BC,CD</td>
<td>2.75 ± 0.51AB,CD</td>
<td>557 ± 99B</td>
</tr>
</tbody>
</table>

Values are mean ± SE, n = 9–10 per group. See Methods for abbreviations. *Significantly different from sham-vehicle; P < 0.05. †Significantly different from OVX-vehicle; P < 0.05. ‡Significantly different from OVX-estradiol; P < 0.05. §Significantly different from OVX-NPS 2143; P < 0.05.
turnover was elevated but the balance was positive, resulting in net bone gain. When PTH was elevated to similar levels for longer than 4 hours in NPS 2143–treated animals, bone turnover was further elevated. However, both resorption and formation remained in balance, leading to no net loss or gain in bone mass. It is well known that chronic elevation of PTH, such as that seen in hyperparathyroidism, leads to bone loss and abnormal bone histology (33, 34). Dobnig and Turner (35) showed that subcutaneous infusion of high doses of PTH (40 μg/kg and 80 μg/kg) over periods of 2 or more hours each day for 7 days leads to rapid body weight loss, hypercalcemia, and histological abnormalities in the skeleton similar to those seen in patients with hyperparathyroidism. In our study, the much smaller increases in PTH, although sustained, did not lead to these adverse effects. It has been shown previously that substantial cancellous bone loss occurs in rats with mild secondary hyperparathyroidism (two- to threefold increases in PTH levels) resulting from chronic renal insufficiency (34). Although an anabolic effect of PTH was not obtained with the more sustained exposure in the current study, the fact that bone loss was not exaggerated in rats given NPS 2143 suggests that the duration rather than the magnitude of the PTH response was insufficient to cause a worsening of the osteopenia. Indeed, plasma levels of PTH were normal, and NPS 2143 was undetectable in the circulation by 24 hours after the oral dose. This suggests that a shorter-acting compound that induces a more transient increase in PTH levels might induce a net anabolic effect on bone.

A further point of interest with regard to the amount of PTH secreted in response to NPS 2143 is the small magnitude of increase in PTH levels required to have profound effects on bone turnover. We showed previously that doses of rat PTH(1-34) as low as 1 μg/kg (which increase PTH levels by approximately threefold) increase bone formation in OVX rats (22). In contrast, most published studies on effects of PTH in rats have used a dose of 80 μg/kg. When injected subcutaneously, this dose leads to a circulating level of approximately 10,000 pg/mL (35), compared with the 100–200 pg/mL in our studies. This clearly demonstrates that very small increases in the plasma levels of PTH are effective in stimulating bone metabolism. This is also illustrated by the much lower doses used in the clinical studies performed recently in which PTH doses of about 0.4–0.8 μg/kg body weight increased bone mass substantially (8–13). The 0.4 μg/kg dose increased plasma levels of PTH(1-34) to approximately 90 pmol/L at 30 minutes after dosing.
This represents an approximately threefold increase over the baseline circulating level of endogenous PTH in these patients. Thus it appears that the repeated transient elevation of circulating PTH levels by a short-acting Ca\textsuperscript{2+} receptor antagonist are quite sufficient to cause an anabolic effect in bone.

One potential concern with repeated stimulation of the parathyroid gland is that it may induce parathyroid cell hyperplasia. It is well recognized that the parathyroid glands are larger in rats fed a low-calcium diet (37). Naveh-Many et al. (38) showed markedly increased parathyroid cell proliferation in weanling rats fed a low-calcium diet for 3 weeks. In contrast, Wernerson et al. (39) showed in older calcium-deficient rats that this glandular enlargement resulted exclusively from hypertrophy of the parathyroid cells, and not from hyperplasia. The results of our studies, showing that a hyperplastic response does not occur even with the extended duration of stimulation to parathyroid cells induced by treatment with NPS 2143, are consistent with those of Wernerson et al.

Numerous studies have been performed in the O VX rat to determine whether concurrent antiresorptive treatment affects the anabolic effect of PTH. Studies have shown that the bone formation effect of PTH in O VX rats is not ablated by estrogen, calcitonin, or the bisphosphonate risedronate (40–43). However, one study did show an inhibition of bone turnover and a dramatic decrease in bone formation rate when the bisphosphonate tiludronate was used in conjunction with PTH in elderly ewes (44). The authors of that study suggested that bone turnover is required in order for PTH to have an anabolic effect. Our study showed that new bone formation occurred in the absence of previous resorption, which would appear to contradict those findings. It is possible that the effects in rats and sheep may be different. However, it is clear that in postmenopausal women, the anabolic effect of PTH is demonstrable in the presence of estrogen (10, 11, 13). Our studies also suggest that even a long-acting calcilytic could have therapeutic benefits if administered concurrently with estrogen.

There have been reports of Ca\textsuperscript{2+} receptors on both osteoclasts and osteoblasts. Receptors that are both similar to (45, 46) and distinct from (47) the one known receptor have been reported on osteoblasts in vitro. Ca\textsuperscript{2+} receptors have also been characterized pharmacologically on osteoclasts (48), but there is no evidence to suggest that this receptor is structurally similar to that on the parathyroid cell, and it is known to be distinct pharmacologically (49). Moreover, although previous studies have shown that NPS 2143 does not act on structurally similar metabotropic glutamate and GABA\textsubscript{B} receptors (23), it may act on other receptors. Particularly important in this regard are PTH receptors in bone. Any activity of a Ca\textsuperscript{2+} receptor antagonist on PTH receptors at this site could easily abolish the desired effect on bone and instead cause something quite undesirable. Indeed, actions of NPS 2143 on any of a number of different receptors expressed in bone could render this class of compounds therapeutically useless. For this reason, we examined the effects of NPS 2143 in a number of assays that monitor functional activity of bone cells in

### Figure 10
NPS 2143 does not affect basal or PTH-stimulated cyclic AMP formation or alkaline phosphatase activity in TF274 osteoblastic cells. Values are mean ± SE of experiments performed in triplicate.
vitro, both in the presence and absence of PTH. Of the five different assays used, only the fetal rat long bone assay detected an effect of NPS 2143. The inhibitory effect on resorption in this assay was not seen using isolated human osteoclasts, and even in the rat assay, inhibitory effects of NPS 2143 were seen only at concentrations (IC50 = 11 μM) far in excess of those required to block the parathyroid Ca2+ receptor (IC50 = 0.043 μM). Taken together, the data suggest that NPS 2143, when used at concentrations that maximally inhibit Ca2+ receptor activity, does not affect bone cell activity. This suggests that the increased bone resorption seen in rats treated with NPS 2143 results solely from the prolonged exposure to elevated PTH levels.

It has not escaped our attention that the failure of a potent Ca2+ receptor antagonist to affect bone resorption in vitro probably has implications for the controversy regarding the presence (or absence) of the Ca2+ receptor in skeletal tissues (46–50). However, our data do not directly address this issue and therefore should not be used to support either argument. The pharmacological properties of receptors are known to differ depending on the cellular environment in which they are expressed (51). The Ca2+ receptor is no exception, and displays a very different pharmacology in C cells than in parathyroid cells, at least in response to Ca2+ receptor agonist (calcimimetic) compounds (52, 53).

In conclusion, we have provided proof-of-concept for the view that stimulation of endogenous PTH secretion using an antagonist of the parathyroid cell Ca2+ receptor results in increased bone formation and resorption. In the presence of an antiresorptive agent, NPS 2143 caused an increase in bone mass. These findings provide the basis for the development of calcilytics, a novel class of anabolic agents for the treatment of established osteoporosis.

Acknowledgments

The authors thank Sandra Hoffman, Peter Liang, Janice Vasco-Moser, Beata Lechowska, and Uma Prabhakar for excellent technical assistance, and Michael W. Lark, Larry J. Suva, and John C. Lee for editorial input.